Siegfried Evionnaz operates as a drug-substance development and manufacturing site within the Siegfried Group’s global CDMO network. With its 4,500 m² R&D Center for Drug Substances inaugurated in late 2024, the site strengthens its role in complex API process development and industrial execution.

Located in Evionnaz (Valais), the site focuses on chemical process development and API manufacturing for innovative and generic medicines.

It is part of the Siegfried Group, founded in 1873 and headquartered in Zofingen.

At Group level, Siegfried reported in 2025:

• CHF 1.33 billion in sales

• Core EBITDA margin of 22%

• More than 3,800 employees worldwide

• 13 sites across Europe, the United States and Asia

These figures reflect continued growth under the Group’s EVOLVE+ strategy and sustained demand for integrated drug-substance and drug-product capabilities.

Within this structure, Evionnaz contributes dedicated expertise in API development and industrialization.

R&D infrastructure dedicated to process indutrialization

Siegfried Evionnaz operates as a drug-substance development and manufacturing site within the Siegfried Group’s global CDMO network. With its 4,500 m² R&D Center for Drug Substances inaugurated in late 2024, the site strengthens its role in complex API process development and industrial execution.

Technologies supporting process industrialization

The R&D Center integrates capabilities that matter for late-stage development and robust transfer to manufacturing, including:

• Flow chemistry

• Advanced distillation

• Process Analytical Technology (PAT)

Capabilities in complex chemical synthesis

Siegfried Evionnaz positions itself on demanding small molecule chemistry.

Core competencies include:

• Multi-step organic synthesis

• Catalytic transformations

• Flow chemistry integration

• Advanced distillation technologies

• Process Analytical Technology (PAT) implementation

These capabilities support impurity control strategies, robustness at scale and lifecycle continuity from development to commercial supply.

Production infrastructure is modular and adaptable, enabling both clinical-phase supply and commercial manufacturing within the same industrial environment.

Industrial positioning within the Siegfried network

Siegfried combines drug-substance and drug-product expertise across its global footprint.

Within this integrated CDMO model, Evionnaz plays a defined role in:

• API process development

• Industrialization of complex molecules

• European manufacturing capacity

The site contributes to global project execution while operating within Swiss industrial standards and regulatory frameworks.